CorMedix Inc.
(CRMD)
undefined
undefined%
At close: undefined
8.18
0.12%
After-hours Jan 03, 2025, 04:00 PM EST
Company Description
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally.
Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology.
The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007.
CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
CorMedix Inc.
| Country | United States |
| IPO Date | May 13, 2010 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 82 |
| CEO | Joseph Todisco MBA |
Contact Details
Address: 300 Connell Drive Berkeley Heights, New Jersey United States | |
| Website | https://www.cormedix.com |
Stock Details
| Ticker Symbol | CRMD |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001410098 |
| CUSIP Number | 21900C308 |
| ISIN Number | US21900C3088 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Joseph Todisco MBA | Chief Executive Officer & Director |
| Dr. Matthew T. David M.D. | Executive Vice President & Chief Financial Officer |
| Kaufman Beth Zelnick Esq. | Executive Vice President, Chief Legal Officer & Corporate Secretary |
| Donna Ucci | Senior Vice President & Head of Global Quality |
| Dr. Tushar Mukherjee | Senior Vice President & Head of Technical Operations |
| Elizabeth Masson-Hurlburt B.A. | Executive Vice President and Chief Clinical Strategy & Operations Officer |
| Erin Mistry | Executive Vice President & Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 18, 2024 | 4/A | [Amend] Filing |
| Dec 16, 2024 | 4 | Filing |
| Dec 13, 2024 | 4 | Filing |
| Nov 25, 2024 | 8-K | Current Report |
| Nov 18, 2024 | 4 | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Oct 30, 2024 | 10-Q | Quarterly Report |
| Oct 30, 2024 | 8-K | Current Report |
| Oct 08, 2024 | DEF 14A | Filing |
| Aug 14, 2024 | 10-Q | Quarterly Report |